鹽酸安非他酮緩釋片治療抑郁癥的雙盲雙模擬隨機對照試驗_《中國循證醫學雜志》

作者：

王雪 , 張波 , 李靜 ,  孫學禮

四川大學華西醫院精神科（成都 610041）;

關鍵詞：

鹽酸安非他酮緩釋片氟西汀片抑郁癥臨床療效藥物安全性隨機對照試驗

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的　評價鹽酸安非他酮緩釋片治療抑郁癥的療效和安全性。
方法　采用隨機雙盲雙模擬方法，將符合CCMD-3有關單相抑郁發作和雙相情感障礙抑郁發作標準的患者48例，隨機分為安非他酮組和氟西汀組。兩組患者于清洗3~7天后分別給予鹽酸安非他酮緩釋片300 mg/d和氟西汀片20 mg/d，療程均為42天。臨床療效觀察采用漢密爾頓抑郁量表（HAMD）評分、漢密爾頓焦慮量表（HAMA）評分、臨床總體印象量表（CGI）評分和治療藥物副作用量表（TESS），實驗室檢查包括血常規、小便常規、生化和心電圖。
結果　兩組基線與治療各階段HAMD量表、HAMA量表評分的變化情況顯示：安非他酮組治療有效率83.3%（20/ 24），氟西汀組為62.5%（15/24）；兩組不良反應率均為45.9%（11/24），未見嚴重不良反應。
結論　安非他酮和氟西汀組療效相當，能有效治療抑郁癥及伴隨焦慮癥狀，不良反應輕微。

引用本文： 王雪,張波,李靜,孫學禮. 鹽酸安非他酮緩釋片治療抑郁癥的雙盲雙模擬隨機對照試驗. 中國循證醫學雜志, 2007, 07(6): 409-414. doi: 復制

1.	Tomarken AJ, Dichter GS, Freid C, et al. Assessing the effects of bupropion SR on mood dimensions of depression. J Affect Disord, 2004, 78(3): 235-241.
2.	Glod CA, Lynch A, Flynn E, et al. Open trial of bupropion SR in adolescent major depression. J Child Adolesc Psychiatr Nurs, 2003, 16(3): 123-130.
3.	Jamerson BD, Krishnan KR, Roberts J, et al. Effect of bupropion SR on specific symptom clusters of depression: analysis of the 31-item Hamilton Rating Scale for depression. Psychopharmacol Bull, 2003, 37(2): 67-78.
4.	Croft H, Houser TL, Jamerson BD, et al. Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks. Clin Ther, 2002, 24(4): 662-672.
5.	Weihs KL, Houser TL, Batey S R, et al. Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biol Psychiatry, 2002, 51(9): 753-761.
6.	Nieuwstraten CE, Dolovich LR. Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression. Ann Pharmacother, 2001, 35(12): 1608-1613.
7.	Steffens DC, Doraiswamy PM, McQuoid DR. Bupropion SR in the naturalistic treatment of elderly patients with major depression. Int J Geriatr Psychiatry, 2001, 16(9): 862-865.
8.	Weihs KL, Sette EC Jr, Batey SR, et al. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry, 2000, 61(3): 196-202.
9.	Daviss WB, Bentivoglio P, Racusin R, et al. Bupropion sustained release in adolescents with attention-deficit/hyperactivity disorder and depression. J Am Acad Child Adolesc Psychiatry, 2001, 40(3): 307-314.
10.	Leentjens AF, Verhey FR, Vreeling FW. Successful treatment of depression in a Parkinson disease patient with bupropion. Ned Tijdschr Geneeskd, 2000, 144(45): 2157-2159.
11.	Fatemi SH, Emamian ES, Kist DA. Venlafaxine and bupropion combination therapy in a case of treatment-resistant depression. Ann Pharmacother, 1999, 33(6): 701-703.
12.	Marshall RD, Liebowitz MR. Paroxetine/bupropion combination treatment for refractory depression. J Clin Psychopharmacol,1996, 16(1): 80-81.
13.	Apter JT, Kushner SF, Woolfolk RL. Bupropion/nortriptyline combination for refractory depression. Ann Clin Psychiatry, 1994, 6(4): 255-258.
14.	Settle EC, Stahl SM, Batey SR, et al. Safety profile of sustained-release bupropion in depression: results of three clinical trials. Clin Ther, 1999, 21(3): 454-463.

1. Tomarken AJ, Dichter GS, Freid C, et al. Assessing the effects of bupropion SR on mood dimensions of depression. J Affect Disord, 2004, 78(3): 235-241.
2. Glod CA, Lynch A, Flynn E, et al. Open trial of bupropion SR in adolescent major depression. J Child Adolesc Psychiatr Nurs, 2003, 16(3): 123-130.
3. Jamerson BD, Krishnan KR, Roberts J, et al. Effect of bupropion SR on specific symptom clusters of depression: analysis of the 31-item Hamilton Rating Scale for depression. Psychopharmacol Bull, 2003, 37(2): 67-78.
4. Croft H, Houser TL, Jamerson BD, et al. Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks. Clin Ther, 2002, 24(4): 662-672.
5. Weihs KL, Houser TL, Batey S R, et al. Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biol Psychiatry, 2002, 51(9): 753-761.
6. Nieuwstraten CE, Dolovich LR. Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression. Ann Pharmacother, 2001, 35(12): 1608-1613.
7. Steffens DC, Doraiswamy PM, McQuoid DR. Bupropion SR in the naturalistic treatment of elderly patients with major depression. Int J Geriatr Psychiatry, 2001, 16(9): 862-865.
8. Weihs KL, Sette EC Jr, Batey SR, et al. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry, 2000, 61(3): 196-202.
9. Daviss WB, Bentivoglio P, Racusin R, et al. Bupropion sustained release in adolescents with attention-deficit/hyperactivity disorder and depression. J Am Acad Child Adolesc Psychiatry, 2001, 40(3): 307-314.
10. Leentjens AF, Verhey FR, Vreeling FW. Successful treatment of depression in a Parkinson disease patient with bupropion. Ned Tijdschr Geneeskd, 2000, 144(45): 2157-2159.
11. Fatemi SH, Emamian ES, Kist DA. Venlafaxine and bupropion combination therapy in a case of treatment-resistant depression. Ann Pharmacother, 1999, 33(6): 701-703.
12. Marshall RD, Liebowitz MR. Paroxetine/bupropion combination treatment for refractory depression. J Clin Psychopharmacol,1996, 16(1): 80-81.
13. Apter JT, Kushner SF, Woolfolk RL. Bupropion/nortriptyline combination for refractory depression. Ann Clin Psychiatry, 1994, 6(4): 255-258.
14. Settle EC, Stahl SM, Batey SR, et al. Safety profile of sustained-release bupropion in depression: results of three clinical trials. Clin Ther, 1999, 21(3): 454-463.

《中國循證醫學雜志》

鹽酸安非他酮緩釋片治療抑郁癥的雙盲雙模擬隨機對照試驗

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《中國循證醫學雜志》

鹽酸安非他酮緩釋片治療抑郁癥的雙盲雙模擬隨機對照試驗

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料